(CercleFinance.com) – The Sartorius Stedim Biotech share posted the strongest growth in the SBF 120 index on Thursday morning, with investors welcoming the first-half results of this supplier of equipment and services for the biopharmaceutical industry.
Despite a context deemed ‘increasingly difficult’, the Aubagne-based group – which helps its customers to manufacture medicines – recorded double-digit growth in its turnover and its results during the first six months of the year, while confirming its objectives for the year as a whole.
During the first half, sales increased by 22.1% year-on-year and at constant exchange rates (+27.5% as reported) to reach approximately 1,724 million euros.
Its current EBITDA increased by 24.5% to 607 million euros during the first half, corresponding to a margin of 35.2% against 36.1% over the same period last year.
The company explains this decline by an increase in its costs following the recruitment of new employees, as well as by the resumption of business travel.
Management has confirmed its forecasts for the whole of the current financial year, still aiming for growth in turnover of 15% to 19% for an Ebitda margin of more than 35%.
In its press release, the company nevertheless expressed “still significant uncertainties in the face of the global political and economic situation”, a finding that did not seem to scare investors.
At 11:10 a.m., the stock gained more than 8% in sustained volumes while at the same time, the SBF 120 fell by around 0.1%.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about SARTORIUS STED BIO in real time: